Literature DB >> 9094625

Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1.

M A Brehm1, R H Bonneau, D M Knipe, S S Tevethia.   

Abstract

Replication-deficient viruses provide an attractive alternative to conventional approaches used in the induction of antiviral immunity. We have quantitatively evaluated both the primary and memory cytotoxic T-lymphocyte (CTL) responses elicited by immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1). In addition, we have examined the potential role of these CTL in protection against HSV infection. Using bulk culture analysis and limiting-dilution analysis, we have shown that a replication-deficient virus, d301, generates a strong primary CTL response that is comparable to the response induced by the wild type-strain, KOS1.1. Furthermore, the CTL induced by d301 immunization recognized the immunodominant, H-2Kb-restricted, CTL recognition epitope gB498-505 to a level similar to that for CTL from KOS1.1-immunized mice. The memory CTL response evoked by d301 was strong and persistent, even though the frequencies of CTL were slightly lower than the frequencies of CTL induced by KOS1.1. Adoptive transfer studies indicated that both the CD8+ and the CD4+ T-cell responses generated by immunization with d301 and KOS1.1 were able to limit the extent of a cutaneous HSV infection to comparable levels. Overall, these results indicate that viral replication is not necessary to elicit a potent and durable HSV-specific immune response and suggest that replication-deficient viruses may be effective in eliciting protection against viral pathogens.

Entities:  

Mesh:

Year:  1997        PMID: 9094625      PMCID: PMC191500     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  77 in total

1.  Cell-mediated immunity in herpes simplex virus-infected mice: induction, characterization and antiviral effects of delayed type hypersensitivity.

Authors:  A A Nash; H J Field; R Quartey-Papafio
Journal:  J Gen Virol       Date:  1980-06       Impact factor: 3.891

2.  Cell-mediated immunity in herpes simplex virus-infected mice: functional analysis of lymph node cells during periods of acute and latent infection, with reference to cytotoxic and memory cells.

Authors:  A A Nash; R Quartey-Papafio; P Wildy
Journal:  J Gen Virol       Date:  1980-08       Impact factor: 3.891

3.  Cell-mediated immunity in herpes simplex virus-infected mice: H-2 mapping of the delayed-type hypersensitivity response and the antiviral T cell response.

Authors:  A A Nash; J Phelan; P Wildy
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  Monensin inhibits the processing of herpes simplex virus glycoproteins, their transport to the cell surface, and the egress of virions from infected cells.

Authors:  D C Johnson; P G Spear
Journal:  J Virol       Date:  1982-09       Impact factor: 5.103

5.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.

Authors:  C Taswell
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

6.  A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].

Authors:  A G Langenberg; R L Burke; S F Adair; R Sekulovich; M Tigges; C L Dekker; L Corey
Journal:  Ann Intern Med       Date:  1995-06-15       Impact factor: 25.391

7.  Frequency of cytotoxic T lymphocyte precursors to herpes simplex virus type 1 as determined by limiting dilution analysis.

Authors:  B T Rouse; H S Larsen; H Wagner
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

8.  The involvement of herpes simplex virus type 1 glycoproteins in cell-mediated immunity.

Authors:  V C Carter; P A Schaffer; S S Tevethia
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

9.  Pathogenesis of herpes simplex virus in congenitally athymic mice: the relative roles of cell-mediated and humoral immunity.

Authors:  A K Kapoor; A A Nash; P Wildy; J Phelan; C S McLean; H J Field
Journal:  J Gen Virol       Date:  1982-06       Impact factor: 3.891

10.  Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.

Authors:  R D Dix; L Pereira; J R Baringer
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

View more
  14 in total

1.  Herpes simplex virus vectors elicit durable immune responses in the presence of preexisting host immunity.

Authors:  Mark A Brockman; David M Knipe
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

2.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

4.  Optimal long-term humoral responses to replication-defective herpes simplex virus require CD21/CD35 complement receptor expression on stromal cells.

Authors:  Mark A Brockman; Admar Verschoor; Jia Zhu; Michael C Carroll; David M Knipe
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

5.  Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus.

Authors:  M Franchini; C Abril; C Schwerdel; C Ruedl; M Ackermann; M Suter
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 6.  The dynamics of the cellular immune response to HIV infection: implications for vaccination.

Authors:  A J McMichael; M Callan; V Appay; T Hanke; G Ogg; S Rowland-Jones
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-08-29       Impact factor: 6.237

7.  Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of a replication-incompetent herpes simplex virus type 1 vaccine strain.

Authors:  B J Geiss; T J Smith; D A Leib; L A Morrison
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

8.  Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens.

Authors:  Anna Lang; James D Brien; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  The dominant-negative herpes simplex virus type 1 (HSV-1) recombinant CJ83193 can serve as an effective vaccine against wild-type HSV-1 infection in mice.

Authors:  Hanka Augustinova; Daniela Hoeller; Feng Yao
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

10.  Production of immunogenic West Nile virus-like particles using a herpes simplex virus 1 recombinant vector.

Authors:  Travis J Taylor; Fernando Diaz; Robert C Colgrove; Kristen A Bernard; Neal A DeLuca; Sean P J Whelan; David M Knipe
Journal:  Virology       Date:  2016-06-20       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.